AKEBIA THERAPEUTICS INC's ticker is AKBA and the CUSIP is 00972D105. A total of 133 filers reported holding AKEBIA THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.20 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $5,862,864 | -75.7% | 5,747,906 | -56.5% | 11.49% | -54.8% |
Q1 2024 | $24,165,368 | +20.3% | 13,205,119 | -18.5% | 25.42% | -4.9% |
Q4 2023 | $20,094,348 | +8.8% | 16,205,119 | 0.0% | 26.74% | -15.3% |
Q3 2023 | $18,473,836 | +24.6% | 16,205,119 | 0.0% | 31.57% | +63.7% |
Q2 2023 | $14,827,684 | +63.3% | 16,205,119 | 0.0% | 19.29% | +60.8% |
Q1 2023 | $9,081,349 | +4.3% | 16,205,119 | +7.4% | 12.00% | +19.8% |
Q4 2022 | $8,706,999 | +491.9% | 15,090,119 | +224.3% | 10.02% | +607.3% |
Q3 2022 | $1,471,000 | -10.4% | 4,652,561 | 0.0% | 1.42% | -53.5% |
Q2 2022 | $1,642,000 | -50.8% | 4,652,561 | 0.0% | 3.05% | -46.1% |
Q1 2022 | $3,340,000 | -68.2% | 4,652,561 | 0.0% | 5.66% | -47.1% |
Q4 2021 | $10,515,000 | -21.5% | 4,652,561 | 0.0% | 10.70% | +16.6% |
Q3 2021 | $13,399,000 | -24.0% | 4,652,561 | 0.0% | 9.17% | -4.2% |
Q2 2021 | $17,633,000 | +12.0% | 4,652,561 | 0.0% | 9.57% | +37.4% |
Q1 2021 | $15,749,000 | +20.9% | 4,652,561 | 0.0% | 6.97% | +35.8% |
Q4 2020 | $13,027,000 | – | 4,652,561 | – | 5.13% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Consonance Capital Management LP | 7,121,283 | $53,979,000 | 4.02% |
DAFNA Capital Management LLC | 853,538 | $6,470,000 | 2.70% |
Baupost Group | 17,527,968 | $132,862,000 | 1.96% |
Nantahala Capital Management | 6,559,478 | $49,721,000 | 1.86% |
Novo Holdings A/S | 3,393,039 | $25,719,000 | 1.72% |
Abrams Capital Management | 5,656,462 | $42,876,000 | 1.69% |
Stanley-Laman Group, Ltd. | 319,073 | $2,419,000 | 0.73% |
Integral Health Asset Management, LLC | 200,000 | $1,516,000 | 0.67% |
KNOTT DAVID M | 135,169 | $1,025,000 | 0.65% |
Leap Investments LP | 54,700 | $415,000 | 0.61% |